Ravindra Mehrotra's questions to Cyclerion Therapeutics (CYCN) leadership • Q1 2019
Question
Ravindra Mehrotra asked for more detail on the company's team, culture, and the collective experience that has enabled it to execute so quickly since its launch.
Answer
CEO Peter Hecht described the team as a blend of experienced personnel from their previous work at Ironwood and new talent from other leading companies, such as Dr. Andy Busch, who previously led R&D at Shire and played a key role in sGC stimulator development at Bayer. Hecht emphasized that the new company's culture is built on urgency, focus, and operational excellence, which is particularly effective in the orphan disease space where they can work constructively with regulatory agencies to potentially accelerate development timelines.